Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT04774445
This protocol aims to evaluate the efficacy of a theoretically and stakeholder informed patient-centered genetic Interactive Health Communication Application to increase patient understanding of, and affective and behavioral responses to genetic testing. The study investigators hypothesize that the intervention will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in performance of risk reducing health behaviors.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
Philadelphia, Pennsylvania, 19104, United States
As clinical practice increasingly use multi-gene testing, many patients are left with unknowns after genetic testing. Many have results that are unclear and may or may not be associated with any risk for cancer (Variants of Uncertain Significance), or mutations in genes with very limited information about disease risk or the best medical management. Importantly, many of these uncertainties will be clarified over time, but there is a need for effective ways of communicating these updates to patients who had testing months or years ago. In some cases, there may be multiple updates over time. To address this, this study will provide patients access, using an Interactive Health Communication Application, MyCancerGene, to information about their genetic testing, their specific results and the implications, the ability to print reports and other materials for their relatives and other health care providers and to assess if there has been a change in the personal or family history. Additionally, patients can contact their genetic provider through MyCancerGene and the cancer genetics team can send out updates to patients about their individual results or about new information about risk estimates or screening recommendations. The study investigators hypothesize that MyCancerGene will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in cancer screening and risk reducing health behaviors. After 12 months, all patients will have access to MyCancerGene, which will aid in understanding who benefits most and least from this intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
•No internet and/or mobile access
Interactive Health Communication Application
Time frame: Baseline - 18 Months
Change in Knowledge. Score Range = 0-16. Higher score = Better outcome
Time frame: Baseline - 18 Months
Change in General Anxiety and Depression. Score Range = 4-20 for Anxiety/4-20 for Depression. Lower score = Better outcome
Time frame: Baseline - 18 Months
Change in Uncertainty. Score Range = 0-85. Lower score = Better outcome
Time frame: Baseline - 18 months
Change in Disease-Specific Distress. Score Range =0-40. Lower score = Better outcome
Time frame: Baseline - 18 months
Single item assessing participants' ability to accurately recall their genetic test result. Single answer multiple choice: Positive, Negative, Variant of Uncertain Significance
Time frame: Baseline - 18 months
Quantitative scales assessing changes in perceived risk, timeline and utility.
Time frame: Baseline - 18 months
Changes in modifiable cancer lifestyle behaviors. Yes/No responses.
Time frame: Baseline - 18 months
Changes in diet and exercise. Yes/No responses.
Time frame: Baseline - 18 months
Assesses the number of relatives and health care providers patients share genetic test results with
Abramson Cancer Center at Penn Medicine
Other
Acronym: MyCancerGene
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04141462
Cancer, Disease Attributes
Besançon, France
View Trial DetailsNCT04620278
Cancer, Disease
San Antonio, Texas, United States
View Trial DetailsNCT06533189
Cancer, Disease Attributes
Roma, Italy
View Trial DetailsNCT06584994
Cancer, Disease Attributes
Cambridge, United Kingdom
View Trial Details